RT Journal Article
SR Electronic
T1 The impact of asthma severity on the total cost of asthma patients in the Valencia Region
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P707
VO 42
IS Suppl 57
A1 Luis Lizán
A1 Concha Álvarez Sanz
A1 M. Eugenia Ojanguren
A1 Margarita Capel
A1 Silvia Paz
A1 Esther Compes García
A1 Juan Jose Liñana Santafé
A1 Gema Mencia Sánchez
A1 Luis Ángel Navarro Seisdedos
A1 Jorge Pascual Bernabeu
A1 Fernando Sánchez-Toril
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P707.abstract
AB RATIONALE: To determine the impact of asthma severity on the total cost of asthma treatment for patients in the Valencia region public-health system.METHODS: This open-label, multicentre, observational study involved retrospective collection of clinical and socio-demographic data (NCT01114906). Healthcare resource use during the previous 12 months was assessed from patients’ clinical histories, using specialist and primary care records. Population and prevalence data were used to establish the number of participating centres and patients recruited in the three provinces of the Valencia region (conditioned randomised selection). Local source costs were updated to 2012 prices.RESULTS: 261 patients (females 69.7%; age [mean ± standard deviation] 47.2 ± 18.3 years) were recruited from the Allergology and Pulmonology Units of four hospitals in Alicante, Castellón and Valencia. The average cost per patient was €1423 (95% CI: 1261–1585). Pharmacological treatment (54%) and medical visits/hospital admissions (33%) were responsible for the greatest proportion of the total costs. The average costs per patient with intermittent, mild, moderate and severe asthma were €780 (95% CI: 616–944), €1030 (95% CI: 880–1180), €1747 (95% CI: 1444–2050) and €3111 (95% CI: 2300–3922), respectively. Asthma severity had a significant influence on costs related to treatment (p<0.001), diagnostic tests (p=0.005), visits/admissions (p<0.001) and total mean costs (p<0.001).CONCLUSIONS: Asthma severity and control are the main determinants of costs for patients with asthma in the Valencia region. Therapy optimisation is key to achieving improved asthma management and to reduce the cost burden to the public health system.